Novartis announces post-marketing data supporting Gilenya efficacy

Swiss pharma giant Novartis (NOVN: VX) has announced post-marketing data that support Phase III findings on the effectiveness of multiple sclerosis (MS) treatment Gilenya (fingolimod).

Results from the real-world study of 590 people with relapsing-remitting MS receiving treatment with Gilenya show that the drug impacted four key measures of disease activity - relapses, MRI lesions, disability progression and brain shrinkage.

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression. Around 58% showed brain shrinkage levels broadly within the range expected for people without MS.